In this randomized placebo-controlled crossover study, we evaluated whether previously reported cardiovascular benefits of plant-derived inorganic nitrate via NO translate into improved vascular function and blood pressure-lowering in middle-aged and older men and women with treated hypertension.

Atrial fibrillation (AF) is a globally evolving medical challenge with, currently, 4% prevalence in the European Union’s population

Background: Computed tomography (CT) could be a suitable method for acute exclusion of left atrial appendage thrombus (LAAT) prior to cardioversion of atrial fibrillation (AF) and atrial flutter (AFL) at the emergency department. Our aim was to present our experiences with this modality in recent years. Methods: This registry-based observational study was performed at the Department of Emergency Medicine at the Medical University of Vienna, Austria. We studied all consecutive patients with AF and AFL who underwent CT between January 2012 and January 2023 to rule out LAAT before cardioversion to sinus rhythm was attempted. Follow-ups were conducted by telephone and electronic medical records. The main variables of interest were the rate of LAAT and ischemic stroke at follow-up. Results: A total of 234 patients (143 [61%] men; median age 68 years [IQR 57–76], median CHA₂DS₂-VASc 2 [IQR 1–4]) were analyzed. Follow-up was completed in 216 (92%) patients after a median of 506 (IQR 159–1391) days. LAAT was detected in eight patients (3%). A total of 163 patients (72%) in whom LAAT was excluded by CT were eventually successfully cardioverted to sinus rhythm. No adverse events occurred during their ED stay. All patients received anticoagulation according to the CHA₂DS₂-VASc risk stratification, and no patient had suffered an ischemic stroke at follow-up, resulting in an incidence risk of ischemic strokes of 0% (95% CI 0.0–1.2%). Conclusion: LAAT was rare in patients admitted to the ED with AF and AFL who underwent cardiac CT prior to attempted cardioversion. At follow-up, no patient had suffered an ischemic stroke. Prospective studies need to show whether this strategy is suitable for the acute treatment of symptomatic AF in the emergency setting.

Patients with recurrence of atrial tachyarrhythmia after catheter ablation for atrial fibrillation or atrial flutter constitute a rapidly growing cohort, but study-driven treatment recommendations are lacking. The present study aimed to compare the cardioversion success of ibutilide and amiodarone in patients with post-ablation atrial tachyarrhythmia. We included all episodes of post-ablation atrial tachyarrhythmia in patients treated with either intravenous ibutilide or amiodarone at an academic emergency department from 2010 to 2018. The primary endpoint was the conversion to sinus rhythm. The conversion rates were stratified by arrhythmia type, and multivariable cluster-adjusted logistic regression was used to estimate the effect of ibutilide and amiodarone on cardioversion success, given as the odds ratio (OR) with 95% confidence intervals (95% CI). In total, 109 episodes of 72 patients were analyzed. The conversion rates were 37/49 (76%) for ibutilide and 16/60 (27%) for amiodarone. Compared to amiodarone, ibutilide was associated with higher odds of conversion (multivariable cluster-adjusted OR 5.6, 95% CI 1.3–24.3). The cardioversion success of ibutilide was the highest in atrial flutter (crude OR 19.5, 95% CI 3.4–112.5) and focal atrial tachycardia (crude OR 8.3, 95% CI 1.5–47.2), but it was less pronounced in atrial fibrillation (crude OR 4.5, 95% CI 1.2–17.2). Randomized trials are warranted to confirm our findings.

Background/Objectives: In recent years, awareness of sex disparities in atrial fibrillation (AF) and atrial flutter (AFL) has grown, resulting in significant advancements in sex-specific treatment strategies. As these treatment approaches continue to evolve, it is essential to remain attentive to sex-related issues to ensure equitable care for all patients, a point first emphasised by the 2016 AF guidelines. Our objective was the long-term evaluation of sex-specific treatment standards for acute AF/AFL. Methods: This cohort study included cases of acute AF/AFL treated in the emergency department of the Medical University of Vienna, Austria, between 2012 and 2022. The Kaplan–Meier method was used to analyse time-to-event data. The effect of sex on the time to restoration of sinus rhythm was assessed using the log-rank test for unadjusted models and the likelihood ratio test for adjusted models. The groups were categorised based on cases occurring before and after 2016. Results: A total of 3661 cases (55.7% male) were analysed. Before 2016, sinus rhythm was achieved in 70.8% of males and 71.2% of females; after 2016, these rates were 71.8% and 68.6%, respectively. The adjusted model showed a significant effect of sex on the time to restoration of sinus rhythm after 2016 (p = 0.013) but not before (p = 0.865). A subgroup analysis indicated similar results for pharmacologic rhythm control (p = 0.035 vs. p = 0.193). A sensitivity analysis confirmed robustness, with similar effects in both models. The success rate of pharmacological cardioversion was lower in women than in men but was used more frequently in women after 2016. Conclusions: The re-emergence of a sex gap in success rates and time to restoration of sinus rhythm in emergency treatment for acute AF/AFL is concerning and necessitates a re-evaluation of treatment protocols, improved decision-making processes, and further research to ensure equitable, effective, and safe emergency care for all patients.

High sugar consumption is associated with cardiovascular diseases and diabetes. Current sugar substitutes may cause taste sensations and gastrointestinal symptoms. ENSO 16 is a combination of 16 different sugar substitutes and plant fibers and has been designed as a sugar alternative. The impact on plasma glucose metabolism as well as on gastrointestinal tolerance has not been investigated yet. 17 healthy participants were enrolled in this randomized, double-blind trial. Participants received a single oral dose of 30 g glucose or 30 g ENSO 16 and crossed over to the alternate treatment after a 7 day wash out period. The study endpoint was the effect on plasma glucose, insulin, C-peptide concentrations and gastrointestinal disorders. A questionnaire regarding gastrointestinal symptoms was used for individual subjective scoring. The mean baseline adjusted plasma glucose AUC_0–180 min was significantly greater after glucose administration compared to ENSO 16 (n = 15, p = 0.0128, paired t-test). Maximum plasma glucose elevation over baseline was 117 mg*dl⁻¹ and 20 mg*dl⁻¹ after oral glucose or ENSO 16, respectively. Insulin and C-peptide AUC_0−180 min were significantly greater after glucose compared to ENSO 16 intake (p < 0.01, Wilcoxon rank sum test). The mean maximal concentrations of plasma glucose, insulin and C-peptide after glucose intake were 1.5, 4.6 and 2.7-fold greater after glucose intake compared to ENSO 16 intake, respectively. Adverse reactions were mostly mild and not different between treatments. Conclusion. ENSO 16 has only a small impact on plasma glucose metabolism. This may be of interest in a dietary context and may help to reduce calory intake.Trail registration NCT05457400. First registration: 14/07/2022. https://clinicaltrials.gov/study/NCT05457400.